Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 230

The DOI matches its Crossref record.

Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer

Kast, Karin, Rhiem, Kerstin, Wappenschmidt, Barbara, Hahnen, Eric, Hauke, Jan, Bluemcke, Britta, Zarghooni, Verena, Herold, Natalie, Ditsch, Nina, Kiechle, Marion, Braun, Michael, Fischer, Christine, Dikow, Nicola, Schott, Sarah, Rahner, Nils, Niederacher, Dieter, Fehm, Tanja, Gehrig, Andrea, Mueller-Reible, Clemens, Arnold, Norbert, Maass, Nicolai, Borck, Guntram, de Gregorio, Nikolaus, Scholz, Caroline, Auber, Bernd, Varon-Manteeva, Raymonda, Speiser, Dorothee, Horvath, Judit, Lichey, Nadine, Wimberger, Pauline, Stark, Sylvia, Faust, Ulrike, Weber, Bernhard H F, Emons, Gunter, Zachariae, Silke, Meindl, Alfons, Schmutzler, Rita K, Engel, Christoph·2016·Journal of Medical Genetics

Abstract

Purpose: To characterise the prevalence of pathogenic germline mutations in BRCA1 and BRCA2 in families with breast cancer (BC) and ovarian cancer (OC) history. Patients and methods: Data from 21 401 families were gathered between 1996 and 2014 in a clinical setting in the German Consortium for Hereditary Breast and Ovarian Cancer, comprising full pedigrees with cancer status of all individual members at the time of first counselling, and BRCA1/2 mutation status of the index patient. Results: The overall BRCA1/2 mutation prevalence was 24.0% (95% CI 23.4% to 24.6%). Highest mutation frequencies were observed in families with at least two OCs (41.9%, 95% CI 36.1% to 48.0%) and families with at least one breast and one OC (41.6%, 95% CI 40.3% to 43.0%), followed by male BC with at least one female BC or OC (35.8%; 95% CI 32.2% to 39.6%). In families with a single case of early BC (<36 years), mutations were found in 13.7% (95% CI 11.9% to 15.7%). Postmenopausal unilateral or bilateral BC did not increase the probability of mutation detection. Occurrence of premenopausal BC and OC in the same woman led to higher mutation frequencies compared with the occurrence of these two cancers in different individuals (49.0%; 95% CI 41.0% to 57.0% vs 31.5%; 95% CI 28.0% to 35.2%). Conclusions: Our data provide guidance for healthcare professionals and decision-makers to identify individuals who should undergo genetic testing for hereditary breast and ovarian cancer. Moreover, it supports informed decision-making of counselees on the uptake of genetic testing.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jmedgenet-2015-103672

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 230

Metadata

Authors
Kast, K., Rhiem, K., Wappenschmidt, B., Hahnen, E., Hauke, J., Bluemcke, B., Zarghooni, V., Herold, N., Ditsch, N., Kiechle, M., Braun, M., Fischer, C., Dikow, N., Schott, S., Rahner, N., Niederacher, D., Fehm, T., Gehrig, A., Mueller-Reible, C., Arnold, N., Maass, N., Borck, G., de Gregorio, N., Scholz, C., Auber, B., Varon-Manteeva, R., Speiser, D., Horvath, J., Lichey, N., Wimberger, P., Stark, S., Faust, U., Weber, B. H. F., Emons, G., Zachariae, S., Meindl, A., Schmutzler, R. K., & Engel, C.
Venue
Journal of Medical Genetics
Publisher
BMJ
Published
2016-02-29
Volume
53
Issue
7
Pages
465-471
ISSN
  • 0022-2593 (ISSN-L)
  • 1468-6244
OpenAlex
W2289657957
Cited by
230
References
0
FWCI
18.10
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer. https://app.cochat.ai/papers/10.1136/jmedgenet-2015-103672
The paper
Kast, K., Rhiem, K., Wappenschmidt, B., Hahnen, E., Hauke, J., Bluemcke, B., Zarghooni, V., Herold, N., Ditsch, N., Kiechle, M., Braun, M., Fischer, C., Dikow, N., Schott, S., Rahner, N., Niederacher, D., Fehm, T., Gehrig, A., Mueller-Reible, C., . . . Engel, C. (2016). Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer. Journal of Medical Genetics. https://doi.org/10.1136/jmedgenet-2015-103672

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.